268 related articles for article (PubMed ID: 32994268)
1. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Marvyin K; Tjønnfjord EB; Breland UM; Tjønnfjord GE
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32994268
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.
Eyre TA; Clifford R; Roberts C; Boyle L; Francis A; Schuh A; Dutton SJ
BMC Cancer; 2015 Feb; 15():52. PubMed ID: 25775024
[TBL] [Abstract][Full Text] [Related]
5. Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome.
Robak T; Urbańska-Ryś H; Strzelecka B; Krykowski E; Bartkowiak J; Bĺoński JZ; Kordek R; Warzocha K
Eur J Haematol; 2001; 67(5-6):322-7. PubMed ID: 11872081
[TBL] [Abstract][Full Text] [Related]
6. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
7. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
8. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy.
Narayan H; Bandyopadhyay D; Schmidt K; Chachlani N; Hughes M; Paneesha S; Rose P; Borg A
Clin Lab Haematol; 2005 Dec; 27(6):405-8. PubMed ID: 16307545
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Jessa R; Chien N; Villa D; Freeman CL; Slack GW; Savage KJ; Scott DW; Sehn LH; Song KW; Gerrie AS
Br J Haematol; 2022 Oct; 199(2):230-238. PubMed ID: 35961783
[TBL] [Abstract][Full Text] [Related]
11. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
12. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
14. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
Rapiti N; Peer N; Abdelatif N; Rapiti P; Moosa Y
HIV Med; 2022 Sep; 23(8):837-848. PubMed ID: 35229978
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
17. Sustained complete remission in Richter's syndrome.
Heslop HE; Fitzgerald PH; Beard ME
Cancer; 1987 Mar; 59(5):1036-9. PubMed ID: 3815263
[TBL] [Abstract][Full Text] [Related]
18. Richter's syndrome: a novel presentation.
Smyth EF; Bartlett RJ; Shields ML; White TJ; Wengraf C
Ulster Med J; 2003 May; 72(1):58-60. PubMed ID: 12868708
[No Abstract] [Full Text] [Related]
19. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
